197 related articles for article (PubMed ID: 27470985)
21. The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer.
Tayama S; Motohara T; Narantuya D; Li C; Fujimoto K; Sakaguchi I; Tashiro H; Saya H; Nagano O; Katabuchi H
Oncotarget; 2017 Jul; 8(27):44312-44325. PubMed ID: 28574829
[TBL] [Abstract][Full Text] [Related]
22. Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions.
Matte I; Legault CM; Garde-Granger P; Laplante C; Bessette P; Rancourt C; Piché A
Clin Exp Metastasis; 2016 Dec; 33(8):839-852. PubMed ID: 27612856
[TBL] [Abstract][Full Text] [Related]
23. Promotive role of recombinant HE4 protein in proliferation and carboplatin resistance in ovarian cancer cells.
Wang H; Zhu L; Gao J; Hu Z; Lin B
Oncol Rep; 2015 Jan; 33(1):403-12. PubMed ID: 25354091
[TBL] [Abstract][Full Text] [Related]
24. Targeting FOXM1 Improves Cytotoxicity of Paclitaxel and Cisplatinum in Platinum-Resistant Ovarian Cancer.
Westhoff GL; Chen Y; Teng NNH
Int J Gynecol Cancer; 2017 Oct; 27(8):1602-1609. PubMed ID: 28692634
[TBL] [Abstract][Full Text] [Related]
25. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
26. Establishment of Patient-Derived Tumor Xenograft Models of Epithelial Ovarian Cancer for Preclinical Evaluation of Novel Therapeutics.
Liu JF; Palakurthi S; Zeng Q; Zhou S; Ivanova E; Huang W; Zervantonakis IK; Selfors LM; Shen Y; Pritchard CC; Zheng M; Adleff V; Papp E; Piao H; Novak M; Fotheringham S; Wulf GM; English J; Kirschmeier PT; Velculescu VE; Paweletz C; Mills GB; Livingston DM; Brugge JS; Matulonis UA; Drapkin R
Clin Cancer Res; 2017 Mar; 23(5):1263-1273. PubMed ID: 27573169
[No Abstract] [Full Text] [Related]
27. The lncRNA SNHG3 regulates energy metabolism of ovarian cancer by an analysis of mitochondrial proteomes.
Li N; Zhan X; Zhan X
Gynecol Oncol; 2018 Aug; 150(2):343-354. PubMed ID: 29921511
[TBL] [Abstract][Full Text] [Related]
28. Corilagin sensitizes epithelial ovarian cancer to chemotherapy by inhibiting Snail‑glycolysis pathways.
Jia L; Zhou J; Zhao H; Jin H; Lv M; Zhao N; Zheng Z; Lu Y; Ming Y; Yu Y
Oncol Rep; 2017 Oct; 38(4):2464-2470. PubMed ID: 28791374
[TBL] [Abstract][Full Text] [Related]
29. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
30. Single cell sequencing reveals heterogeneity within ovarian cancer epithelium and cancer associated stromal cells.
Winterhoff BJ; Maile M; Mitra AK; Sebe A; Bazzaro M; Geller MA; Abrahante JE; Klein M; Hellweg R; Mullany SA; Beckman K; Daniel J; Starr TK
Gynecol Oncol; 2017 Mar; 144(3):598-606. PubMed ID: 28111004
[TBL] [Abstract][Full Text] [Related]
31. Assessment of False-negative Ascites Cytology in Epithelial Ovarian Carcinoma: A Study of 313 Patients.
Allen VA; Takashima Y; Nayak S; Manahan KJ; Geisler JP
Am J Clin Oncol; 2017 Apr; 40(2):175-177. PubMed ID: 25198110
[TBL] [Abstract][Full Text] [Related]
32. NANOG regulates epithelial-mesenchymal transition and chemoresistance through activation of the STAT3 pathway in epithelial ovarian cancer.
Liu S; Sun J; Cai B; Xi X; Yang L; Zhang Z; Feng Y; Sun Y
Tumour Biol; 2016 Jul; 37(7):9671-80. PubMed ID: 26801672
[TBL] [Abstract][Full Text] [Related]
33. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
Lee YK; Park NH; Lee H
Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
[TBL] [Abstract][Full Text] [Related]
35. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis.
Hu Z; Zhu L; Gao J; Cai M; Tan M; Liu J; Lin B
Tumour Biol; 2015 Sep; 36(9):7269-75. PubMed ID: 25895457
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral interleukin-6 predicts ascites formation in patients with epithelial ovarian cancer: A potential tool for close monitoring.
Masoumi-Moghaddam S; Amini A; Wei AQ; Robertson G; Morris DL
J Ovarian Res; 2015 Aug; 8():58. PubMed ID: 26282935
[TBL] [Abstract][Full Text] [Related]
37. Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery.
Paulsen T; Kærn J; Tropé C
Gynecol Oncol; 2011 Jul; 122(1):83-8. PubMed ID: 21435701
[TBL] [Abstract][Full Text] [Related]
38. High-resolution genomic profiling of carboplatin resistance in early-stage epithelial ovarian carcinoma.
Osterberg L; Levan K; Partheen K; Staaf J; Sundfeldt K; Horvath G
Cytogenet Genome Res; 2009; 125(1):8-18. PubMed ID: 19617691
[TBL] [Abstract][Full Text] [Related]
39. Exosomes in the ascites of ovarian cancer patients: origin and effects on anti-tumor immunity.
Peng P; Yan Y; Keng S
Oncol Rep; 2011 Mar; 25(3):749-62. PubMed ID: 21181093
[TBL] [Abstract][Full Text] [Related]
40. Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer.
Marchini S; Fruscio R; Clivio L; Beltrame L; Porcu L; Fuso Nerini I; Cavalieri D; Chiorino G; Cattoretti G; Mangioni C; Milani R; Torri V; Romualdi C; Zambelli A; Romano M; Signorelli M; di Giandomenico S; D'Incalci M
Eur J Cancer; 2013 Jan; 49(2):520-30. PubMed ID: 22897840
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]